ProMIS Neurosciences (PMN) Cash & Equivalents (2021 - 2026)

ProMIS Neurosciences (PMN) has 6 years of Cash & Equivalents data on file, last reported at $63.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 662.94% year-over-year to $63.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.8 million (up 662.94% YoY) and the FY2025 annual result came in at $6.1 million, down 53.98% from the prior year.
• Cash & Equivalents climbed to $63.8 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $63.8 million in Q1 2026 to a low of $992463.0 in Q2 2024.
• A 5-year average of $11.8 million and a median of $7.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 86.27% — and 2026, when it jumped 662.94%.
• Tracing PMN's Cash & Equivalents over 5 years: stood at $5.9 million in 2022, then soared by 114.41% to $12.6 million in 2023, then gained by 5.5% to $13.3 million in 2024, then plunged by 53.98% to $6.1 million in 2025, then surged by 943.31% to $63.8 million in 2026.
• The last three Cash & Equivalents figures came in at $63.8 million (Q1 2026), $6.1 million (Q4 2025), and $15.4 million (Q3 2025), per Business Quant data.